117 SRES 577 IS: Designating April 2022 as “Parkinson’s Awareness Month”. U.S. Senate 2022-04-06 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

III117th CONGRESS2d SessionS. RES. 577IN THE SENATE OF THE UNITED STATESApril 6, 2022Ms. Stabenow (for herself and Mr. Thune) submitted the following resolution; which was referred to the Committee on the JudiciaryRESOLUTIONDesignating April 2022 as Parkinson’s Awareness Month.

Whereas Parkinson’s disease—(1)affects 1,000,000 individuals in the United States;(2)is the second most common neurodegenerative disease in the world;(3)is believed to be caused by a combination of genetic and environmental factors; and(4)is the 14th leading cause of death in the United States, according to the Centers for Disease Control and Prevention;Whereas it is estimated that, by the year 2037, the number of individuals with Parkinson’s disease in the United States will nearly double, and the disease will cost the United States at least $79,000,000,000 annually;Whereas the symptoms of Parkinson’s disease can include dementia and cognitive impairment, tremors, slowness of movement, freezing in place, inability to walk and maintain balance, speech difficulties, depression, losing the ability to swallow, and a variety of other symptoms;Whereas there are millions of family caregivers, friends, and loved ones whose lives are greatly affected by Parkinson’s disease; andWhereas more research, education, and community support services are needed to—(1)find better treatments and a cure for Parkinson's disease; and(2)maintain dignity for those living with the disease today: Now, therefore, be it

That the Senate—(1)designates April 2022 as Parkinson’s Awareness Month;(2)supports the goals and ideals of Parkinson’s Awareness Month;(3)continues to support research to find better treatments and a cure for Parkinson’s disease;(4)recognizes the individuals living with Parkinson’s disease who participate in vital clinical trials to advance the knowledge of the disease; and(5)commends the dedication of organizations, volunteers, researchers, and millions of individuals across the country working to improve the quality of life of people living with Parkinson’s disease and their families.